Chris Viehbacher, Biogen CEO (Scott Eells/Bloomberg via Getty Images)

Fol­low­ing Alzheimer’s drug ap­proval, an­a­lysts dish on what they ex­pect from Bio­gen in 2023 

Bio­gen has been on a roller coast­er over the past cou­ple of years. It sur­vived the con­tro­ver­sial ap­proval and dis­as­trous roll­out of its first Alzheimer’s drug Aduhelm af­ter da­ta on its sec­ond drug showed promise. And it got ac­cel­er­at­ed ap­proval ear­li­er this month for that drug, to be mar­ket­ed as Leqem­bi.

New CEO Chris Viehbach­er is spear­head­ing a new strat­e­gy, hop­ing to turn Leqem­bi in­to a full ap­proval lat­er this year and march Bio­gen on the come­back path. But in­dus­try an­a­lysts have their own ideas about what to ex­pect fol­low­ing the an­nu­al JP Mor­gan Health­care Con­fer­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.